Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
30.77
+1.52 (5.20%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
30.77
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 6:54 PM EDT
Ultragenyx Pharmaceutical Inc. biotexnologiya kompaniyasi bo'lib, Shimoliy Amerika, Lotin Amerika, Yevropa, Yaqin Sharq, Afrika va Osiyo-Tinch okeani mintaqalarida kam uchraydigan va juda kam uchraydigan genetik kasalliklarni davolash uchun yangi mahsulotlarni aniqlash, sotib olish, ishlab chiqish va tijoratlashtirishga qaratilgan. Uning biologik mahsulotlari orasida X-ga bog'liq gipofosfatemiyani, shuningdek, o'smadan kelib chiqqan osteomalatsiyani davolash uchun fibroblast o'sish omili 23 ni nishonga olgan antitelasi bo'lgan Crysvita (burosumab), shuningdek, Mukopolisakkaridoz VII bo'lgan bolalar va kattalarni davolash uchun ferment o'rnini bosuvchi terapiya Mepsevii, uzun zanjirli yog' kislotalari oksidlanishining buzilishlarini davolash uchun Dojolvi va gomozigota nasliy giperxolesterolemiyani davolash uchun Evkeeza (evinakumab) mavjud. Kompaniyaning 3-bosqichli klinik sinovlarda bo'lgan mahsulot nomzodlari orasida osteogenezis imperfektasini davolash uchun inson monoklonal antikori UX143, Sanfilippo sindromi A tipidagi bemorlarni, yoki MPS IIIA, kam uchraydigan lizosomal saqlash kasalligini davolash uchun AAV9 gen terapiyasi mahsulot nomzodi UX111, glyukogen saqlash kasalligi Ia tipidagi bemorlarni davolash uchun adeno-assotsiatsiyalangan virus 8 (AAV8) gen terapiyasi klinik nomzodi DTX401, ornitin transkarbamilazli bemorlarni davolash uchun AAV8 gen terapiyasi DTX301 va Angelman sindromini davolash uchun antisense oligonukleotid GTX-102 mavjud. Kompaniya, shuningdek, Uilson jigari kasalligini davolash uchun 2-bosqichli klinik sinovda bo'lgan adeno-assotsiatsiyalangan AAV9 gen terapiyasi UX701ni ishlab chiqmoqda. Kompaniya Kyowa Kirin Co., Ltd.; Sent-Luis universiteti; Beylor tadqiqot instituti; REGENXBIO Inc.; GeneTx; Mereo; Pensilvaniya universiteti; Regeneron; va Abeona bilan hamkorlik va litsenziyalash shartnomalariga ega. Ultragenyx Pharmaceutical Inc. 2010-yilda tashkil etilgan va uning shtab-kvartirasi Kaliforniyaning Novato shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director |
| Dr. Eric Crombez M.D. | Chief Medical Officer & Executive VP |
| Mr. Dennis Karl Huang | Chief Technical Operations Officer and Executive VP of Gene Therapy Operations |
| Mr. Erik Harris M.B.A. | Executive VP & Chief Commercial Officer |
| Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP |
| Mr. Howard Horn | Executive VP of Corporate Strategy & CFO |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences |
| Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer |
| Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-12 | S-8 | rare-20260612.htm |
| 2026-05-18 | 8-K | rare-20260514.htm |
| 2026-05-06 | 10-Q | rare-20260331.htm |
| 2026-05-05 | 8-K | rare-20260505.htm |
| 2026-04-02 | 8-K | rare-20260402.htm |
| 2026-03-30 | 8-K | rare-20260330.htm |
| 2026-03-27 | DEFA14A | rare015368-defa14a.htm |
| 2026-03-27 | DEF 14A | lrare2026_def14a.htm |
| 2026-03-12 | 8-K | rare-20260312.htm |
| 2026-02-23 | 8-K | rare-20260223.htm |